These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 35459278)

  • 1. CinA mediates multidrug tolerance in Mycobacterium tuberculosis.
    Kreutzfeldt KM; Jansen RS; Hartman TE; Gouzy A; Wang R; Krieger IV; Zimmerman MD; Gengenbacher M; Sarathy JP; Xie M; Dartois V; Sacchettini JC; Rhee KY; Schnappinger D; Ehrt S
    Nat Commun; 2022 Apr; 13(1):2203. PubMed ID: 35459278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Novel Tool to Identify Bactericidal Compounds against Vulnerable Targets in Drug-Tolerant M. tuberculosis found in Caseum.
    Sarathy JP; Xie M; Jones RM; Chang A; Osiecki P; Weiner D; Tsao WS; Dougher M; Blanc L; Fotouhi N; Via LE; Barry CE; De Vlaminck I; Sherman DR; Dartois VA
    mBio; 2023 Apr; 14(2):e0059823. PubMed ID: 37017524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meropenem-vaborbactam restoration of first-line drug efficacy and comparison of meropenem-vaborbactam-moxifloxacin versus BPaL MDR-TB regimen.
    Singh S; Gumbo T; Alffenaar JW; Boorgula GD; Shankar P; Thomas TA; Dheda K; Malinga L; Raj P; Aryal S; Srivastava S
    Int J Antimicrob Agents; 2023 Dec; 62(6):106968. PubMed ID: 37726063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss-of-function mutations in
    Pandey S; Vilchèze C; Werngren J; Bainomugisa A; Mansjö M; Groenheit R; Miotto P; Cirillo DM; Coulter C; Baulard AR; Schön T; Jacobs WR; Djaout K; Köser CU
    Antimicrob Agents Chemother; 2024 Jan; 68(1):e0109623. PubMed ID: 38038476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Central carbon metabolism remodeling as a mechanism to develop drug tolerance and drug resistance in
    Eoh H; Liu R; Lim J; Lee JJ; Sell P
    Front Cell Infect Microbiol; 2022; 12():958240. PubMed ID: 36072228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Wollamide Cyclic Hexapeptides Synergize with Established and New Tuberculosis Antibiotics in Targeting Mycobacterium tuberculosis.
    Rollo RF; Mori G; Hill TA; Hillemann D; Niemann S; Homolka S; Fairlie DP; Blumenthal A
    Microbiol Spectr; 2023 Aug; 11(4):e0046523. PubMed ID: 37289062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of Mycobacterium tuberculosis H37Ra-infected immunocompetent mice as an in vivo model of persisters.
    Kumari N; Sharma R; Ali J; Chandra G; Singh S; Krishnan MY
    Tuberculosis (Edinb); 2024 Mar; 145():102479. PubMed ID: 38262199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First report of whole-genome analysis of an extensively drug-resistant Mycobacterium tuberculosis clinical isolate with bedaquiline, linezolid and clofazimine resistance from Uganda.
    Kabahita JM; Kabugo J; Kakooza F; Adam I; Guido O; Byabajungu H; Namutebi J; Namaganda MM; Lutaaya P; Otim J; Kakembo FE; Kanyerezi S; Nabisubi P; Sserwadda I; Kasule GW; Nakato H; Musisi K; Oola D; Joloba ML; Mboowa G
    Antimicrob Resist Infect Control; 2022 May; 11(1):68. PubMed ID: 35550202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibiotic Treatment Shapes the Antigenic Environment During Chronic TB Infection, Offering Novel Targets for Therapeutic Vaccination.
    Chuang YM; Dutta NK; Gordy JT; Campodónico VL; Pinn ML; Markham RB; Hung CF; Karakousis PC
    Front Immunol; 2020; 11():680. PubMed ID: 32411131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis.
    Ding Y; Zhu H; Fu L; Zhang W; Wang B; Guo S; Chen X; Wang N; Liu H; Lu Y
    Antimicrob Agents Chemother; 2022 Sep; 66(9):e0065822. PubMed ID: 35924925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamic
    Mota F; Ruiz-Bedoya CA; Tucker EW; Holt DP; De Jesus P; Lodge MA; Erice C; Chen X; Bahr M; Flavahan K; Kim J; Brosnan MK; Ordonez AA; Peloquin CA; Dannals RF; Jain SK
    Nat Commun; 2022 Dec; 13(1):7974. PubMed ID: 36581633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delamanid Kills Dormant Mycobacteria
    Chen X; Hashizume H; Tomishige T; Nakamura I; Matsuba M; Fujiwara M; Kitamoto R; Hanaki E; Ohba Y; Matsumoto M
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vitamin C Potentiates the Killing of Mycobacterium tuberculosis by the First-Line Tuberculosis Drugs Isoniazid and Rifampin in Mice.
    Vilchèze C; Kim J; Jacobs WR
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29298757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the effect of clofazimine against Mycobacterium tuberculosis given alone or in combination with pretomanid, bedaquiline or linezolid.
    Kim S; Louie A; Drusano GL; Almoslem M; Kim S; Myrick J; Nole J; Duncanson B; Peloquin CA; Scanga CA; Yamada W; Neely M; Schmidt S
    Int J Antimicrob Agents; 2022 Feb; 59(2):106509. PubMed ID: 34958863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).
    Liu Y; Matsumoto M; Ishida H; Ohguro K; Yoshitake M; Gupta R; Geiter L; Hafkin J
    Tuberculosis (Edinb); 2018 Jul; 111():20-30. PubMed ID: 30029909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High Prevalence of inhA Promoter Mutations among Patients with Drug-Resistant Tuberculosis in KwaZulu-Natal, South Africa.
    Niehaus AJ; Mlisana K; Gandhi NR; Mathema B; Brust JC
    PLoS One; 2015; 10(9):e0135003. PubMed ID: 26332235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contezolid can replace linezolid in a novel combination with bedaquiline and pretomanid in a murine model of tuberculosis.
    Almeida D; Li S-Y; Lee J; Hafkin B; Mdluli K; Fotouhi N; Nuermberger EL
    Antimicrob Agents Chemother; 2023 Dec; 67(12):e0078923. PubMed ID: 37966090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid.
    Kadura S; King N; Nakhoul M; Zhu H; Theron G; Köser CU; Farhat M
    J Antimicrob Chemother; 2020 Aug; 75(8):2031-2043. PubMed ID: 32361756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analytical and clinical performance characteristics of the Abbott RealTime MTB RIF/INH Resistance, an assay for the detection of rifampicin and isoniazid resistant Mycobacterium tuberculosis in pulmonary specimens.
    Kostera J; Leckie G; Tang N; Lampinen J; Szostak M; Abravaya K; Wang H
    Tuberculosis (Edinb); 2016 Dec; 101():137-143. PubMed ID: 27865383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genotypic and phenotypic comparison of drug resistance profiles of clinical multidrug-resistant Mycobacterium tuberculosis isolates using whole genome sequencing in Latvia.
    Vīksna A; Sadovska D; Berge I; Bogdanova I; Vaivode A; Freimane L; Norvaiša I; Ozere I; Ranka R
    BMC Infect Dis; 2023 Sep; 23(1):638. PubMed ID: 37770850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.